19H Stock Overview A business development company. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Hercules Capital, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Hercules Capital Historical stock prices Current Share Price US$18.07 52 Week High US$20.14 52 Week Low US$15.00 Beta 1.32 1 Month Change 0.067% 3 Month Change 2.72% 1 Year Change 21.44% 3 Year Change 25.14% 5 Year Change 45.19% Change since IPO 59.52%
Recent News & Updates
Third quarter 2024 earnings released: EPS: US$0.43 (vs US$0.19 in 3Q 2023) Nov 01
Second quarter dividend of US$0.48 announced Oct 30
Hercules Capital, Inc. Declares Cash Distribution for the Third Quarter 2024, Payable on November 20, 2024 Oct 28
Hercules Capital, Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 20
Hercules Capital, Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 17 Hologic, Inc. (NasdaqGS:HOLX) agreed to acquire Gynesonics, Inc. for $350 million. Oct 14
See more updates
Third quarter 2024 earnings released: EPS: US$0.43 (vs US$0.19 in 3Q 2023) Nov 01
Second quarter dividend of US$0.48 announced Oct 30
Hercules Capital, Inc. Declares Cash Distribution for the Third Quarter 2024, Payable on November 20, 2024 Oct 28
Hercules Capital, Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 20
Hercules Capital, Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 17 Hologic, Inc. (NasdaqGS:HOLX) agreed to acquire Gynesonics, Inc. for $350 million. Oct 14
KARL STORZ Endoscopy-America, Inc. completed the acquisition of Asensus Surgical, Inc. (NYSEAM:ASXC). Aug 23
KARL STORZ Endoscopy-America, Inc. completed the acquisition of Asensus Surgical, Inc. (NYSEAM:ASXC). Aug 22
Second quarter 2024 earnings released: EPS: US$0.26 (vs US$0.66 in 2Q 2023) Aug 04
First quarter dividend of US$0.48 announced Aug 01
Hercules Capital, Inc. Declares Cash Distribution for the Second Quarter 2024, Payable on August 20, 2024 Aug 01
Hercules Capital, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 18
Haveli Investments Software Fund I, L.P., a fund managed by Haveli Investment Management LLC completed the acquisition of ZeroFox Holdings, Inc. (NasdaqGM : ZFOX) from Monarch Alternative Capital LP and Others. May 15
First quarter dividend of US$0.48 announced May 06
First quarter 2024 earnings released: EPS: US$0.58 (vs US$0.69 in 1Q 2023) May 03
Hercules Capital, Inc. Declares First Quarter Cash Dividend, Payable on May 14, 2024 Apr 30
Hercules Capital, Inc., Annual General Meeting, Jun 20, 2024 Apr 24
Hercules Capital, Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 20
KARL STORZ SE & Co. KG entered into an agreement to acquire Asensus Surgical, Inc. (NYSEAM:ASXC) for $100 million. Apr 04
Upcoming dividend of US$0.48 per share Feb 20
Full year 2023 earnings released: EPS: US$2.34 (vs US$0.80 in FY 2022) Feb 16
Hercules Capital, Inc. Declares Cash Distribution for the Fourth Quarter 2023, Dividend Payable on March 6, 2024 Feb 13
Haveli Investments Software Fund I, L.P., a fund managed by Haveli Investment Management LLC entered into an Agreement and Plan of Merger to acquire ZeroFox Holdings, Inc. (NasdaqGM : ZFOX) from Monarch Alternative Capital LP and Others for approximately $150 million. Feb 07
Hercules Capital, Inc. to Report Q4, 2023 Results on Feb 15, 2024 Jan 26
Upcoming dividend of US$0.48 per share at 12% yield Nov 07
Third quarter 2023 earnings released: EPS: US$0.19 (vs US$0.41 in 3Q 2022) Nov 04
Hercules Capital, Inc. Declares Total Cash Distribution the Third Quarter 2023, Payable on November 22, 2023 Nov 01
Hercules Capital, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 13
New major risk - Revenue and earnings growth Oct 07
Hercules Capital Appoints Nikos Theodosopoulos an Independent Member of its Board of Directors and to Serve on Audit Committee Sep 26
Upcoming dividend of US$0.48 per share at 11% yield Aug 10 Hercules Capital, Inc. has completed a Follow-on Equity Offering. Aug 09
New major risk - Revenue and earnings growth Aug 05
Second quarter 2023 earnings released: EPS: US$0.67 (vs US$0.088 loss in 2Q 2022) Aug 05
Hercules Capital Declares Cash Distribution for the Second Quarter 2023, Payable August 25, 2023 Aug 02
Hercules Capital, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 12
Hercules Capital, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 11
Independent Director recently bought €89k worth of stock May 10
Independent Director recently bought €89k worth of stock May 10
First quarter 2023 earnings released: EPS: US$0.70 (vs US$0.033 loss in 1Q 2022) May 06
Investor sentiment deteriorates as stock falls 20% Mar 11
Upcoming dividend of US$0.47 per share at 13% yield Feb 22
Full year 2022 earnings released: EPS: US$0.80 (vs US$1.50 in FY 2021) Feb 20 Hercules Capital Increases Its Quarterly Cash Distribution for the Fourth Quarter of 2022, Payable on March 9, 2023
Hercules Capital, Inc. to Report Q4, 2022 Results on Feb 16, 2023 Feb 03
Hercules Capital, Inc. Announces Resignation of Brad Koenig as Member of the Board Jan 28
Third quarter 2022 earnings released: EPS: US$0.42 (vs US$0.20 in 3Q 2021) Nov 04
Upcoming dividend of US$0.51 per share Nov 02 Sumitovant Biopharma Ltd. signed an agreement to acquire a 47.83% stake in Myovant Sciences Ltd for $1.2 billion. Oct 24
Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of ChemoCentryx, Inc. (NasdaqGS:CCXI) from a group of shareholders. Oct 22
Hercules Capital, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 20
Hercules Capital, Inc. Declares Cash Distribution for the Third Quarter of 2022, Payable on November 17, 2022 Oct 19 Sumitovant Biopharma Ltd. entered into a non-binding proposal to acquire Myovant Sciences Ltd. (NYSE:MYOV) for $1.2 billion. Oct 03
Upcoming dividend of US$0.50 per share Aug 01
Second quarter 2022 earnings released: US$0.083 loss per share (vs US$0.71 profit in 2Q 2021) Jul 30
Hercules Capital, Inc. Increases Quarterly Cash Distribution for the Second Quarter of 2022, Payable on August 16, 2022 Jul 27
Hercules Capital, Inc. to Report Q2, 2022 Results on Jul 28, 2022 Jul 15
Hercules Capital, Inc. Appoints Deanne Aguirre to its Board of Directors Jun 25
First quarter 2022 earnings released: US$0.028 loss per share (vs US$0.56 profit in 1Q 2021) May 07 Hercules Capital, Inc. Announces Cash Distribution for the First Quarter of 2022, Payable on May 24, 2022
Hercules Capital, Inc., Annual General Meeting, Jun 23, 2022 May 02
Hercules Capital, Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 15
Upcoming dividend of US$0.48 per share Mar 01
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
Hercules Capital Declares Cash Distribution for the Fourth Quarter of 2021, Payable on March 16, 2022 Feb 24
Hercules Capital, Inc. to Report Q4, 2021 Results on Feb 22, 2022 Feb 09
Hercules Capital, Inc. Announces Executive Changes Feb 02
High number of new directors Dec 02
High number of new directors Dec 02
Upcoming dividend of US$0.40 per share Nov 02
Third quarter 2021 earnings released: EPS US$0.20 (vs US$0.38 in 3Q 2020) Oct 30
Chief Compliance Officer, General Counsel & Secretary Melanie Grace has left the company Oct 03
Chief Compliance Officer, General Counsel & Secretary Melanie Grace has left the company Sep 29
Upcoming dividend of US$0.39 per share Aug 03
Independent Director Carol Foster has left the company Jul 15
Thoma Bravo, LLC reached an agreement to acquire Greenphire, Inc. from The Riverside Company, Hercules Capital, Inc. (NYSE:HTGC) and Ares Capital Management LLC. May 27
Key Executive recently sold €291k worth of stock May 06
Hercules Capital, Inc. Announces Dividend for the Year 2021 May 01
First quarter 2021 earnings released: EPS US$0.56 (vs US$0.27 loss in 1Q 2020) May 01 Hercules Capital Announces Supplemental Cash Distribution for the First Quarter of 2021, Payable on May 19, 2021
Hercules Capital, Inc. announced that it has received $100 million in funding Mar 06
New 90-day high: €13.68 Mar 04
Upcoming Dividend of US$0.37 Per Share Feb 26
Full year 2020 earnings released: EPS US$2.02 (vs US$1.71 in FY 2019) Feb 25
Revenue beats expectations Feb 25
New 90-day high: €12.58 Feb 04
BridgeBio Pharma, Inc. (NasdaqGS:BBIO) completed the acquisition of remaining 36.3% stake in Eidos Therapeutics, Inc. (NasdaqGS:EIDX). Jan 28
New 90-day high: €11.80 Jan 09
New 90-day high: €11.64 Dec 23
New 90-day high: €11.41 Dec 05 Shareholder Returns 19H DE Capital Markets DE Market 7D -2.2% -2.4% -2.0% 1Y 21.4% 21.1% 6.9%
See full shareholder returns
Return vs Market: 19H exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is 19H's price volatile compared to industry and market? 19H volatility 19H Average Weekly Movement 2.8% Capital Markets Industry Average Movement 4.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 19H has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 19H's weekly volatility (3%) has been stable over the past year.
About the Company Founded Employees CEO Website 2003 100 Scott Bluestein www.htgc.com
Hercules Capital, Inc. is a business development company. The firm specializing in providing private equity, venture debt, and growth capital to privately held venture capital-backed companies at all stages of development from mid venture to expansion stage including select publicly listed companies and select special opportunity companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management buy-out and corporate spin-out financing solutions; company, asset specific, or intellectual property acquisition financing; convertible, subordinated and/or mezzanine loans; domestic and international corporate expansion; vendor financing; revenue acceleration by sales and marketing development, and manufacturing expansion.
Show more Hercules Capital, Inc. Fundamentals Summary How do Hercules Capital's earnings and revenue compare to its market cap? 19H fundamental statistics Market cap €2.95b Earnings (TTM ) €305.16m Revenue (TTM ) €473.84m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 19H income statement (TTM ) Revenue US$494.41m Cost of Revenue US$0 Gross Profit US$494.41m Other Expenses US$176.00m Earnings US$318.41m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 1.99 Gross Margin 100.00% Net Profit Margin 64.40% Debt/Equity Ratio 93.9%
How did 19H perform over the long term?
See historical performance and comparison Dividends
10.0% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 12:19 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Hercules Capital, Inc. is covered by 27 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Bryce Rowe Baird Vernon Plack BB&T Capital Markets Sarkis Sherbetchyan B. Riley Securities, Inc.
Show 24 more analysts 
